A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma

Autor:	Lowell L. Hart, Lynn E. Spitler, J. Zhang, Jose Lutzky, April K.S. Salama, Douglas B. Johnson, Patrick A. Ott, Charles Lance Cowey, Omid Hamid, Aaron R. Alizadeh, J. R. Infante, Neal Evan Rothschild, Anna C. Pavlick, Jason J. Luke, Rebecca G. Bagley, Y. He
Rok vydání:	2016
Předmět:	0301 basic medicine Antibody-drug conjugate GPNMB business.industry Phases of clinical research Hematology 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology Oncology chemistry Cancer research Medicine business Glembatumumab vedotin Advanced melanoma
Zdroj:	Annals of Oncology. 27:vi393
ISSN:	0923-7534
DOI:	10.1093/annonc/mdw379.42
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a1eba33501baf30f86663a4b85a00d59 https://doi.org/10.1093/annonc/mdw379.42 Zobrazit plný text záznamu